Sign in with Google
bullish
Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters
946 Views17 Jul 2019 01:52
Tasly Biopharm, a biologics R&D platform spin-off from A-share listed Tasly Pharmaceutical Group (600535 CH), is looking to raise up to USD 1...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 6-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- CATL H Share Listing: AH Discount Views
- Weekly Deals Digest (04 May) - Toyota Industries, Shibaura, Dickson, HKBN, Meilan Airport, Soundwill
- Last Week in Event SPACE: Toyota, Rio Tinto, Hainan Meilan, Fujitsu General
- Singapore: Lawrence Wong Boosted by Mild Improvement in PAP Vote Share
- Aged Care Sector - Montgomerie-Ibbotson Aged Care Pricing Index
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters17 Jul 2019
x